Biocartis Strengthens Management Team With Chief Commercial Officer

Lausanne, Switzerland And Mechelen, Belgium (ots/PRNewswire) -

Biocartis, a molecular diagnostics company, announces today that
Ulrik Cordes has joined the company as Chief Commercial Officer
(CCO). Ulrik Cordes is an executive with 18+ years of experience in
marketing and sales in the med-tech, pharma and biotech industry, of
which the past 10 years in top level management roles.

"We are delightedtowelcomeUlrik to Biocartis'
ExecutiveTeam,"saidRudi Pauwels, CEO and Chairman of Biocartis. "We
are transforming from a development company into a commercial
business. The addition of Ulrik will be key to achieving our ultimate
goal to making personalized medicine a day-to- day reality by
building a global business. Ulrik possesses a unique combination of
experience and success in building winning commercial strategies and
attracting world class sales and sales support professionals."

Ulrik Cordes joins Biocartis most recently from Thermo Fisher
Scientific, where he held the position of Global Sales & Marketing
Director Slides & Specialty Glass since March 2012. Since 2002 Ulrik
worked at DAKO A/S - A World-leading Company in Cancer Diagnostics,
where he held a number of positions with increasing responsibility,
most recently as Vice President Marketing Operations and Vice
President Asia Pacific & Export Region.

He started his career in 1995 in Pharmacia Biotech A/S (now part
of GE Healthcare). Ulrik received his Master of Science in
Biochemistry from the University of Copenhagen and holds a Bachelor
of Commerce (HD) from Copenhagen Business School.

About Biocartis (http://www.biocartis.com) Biocartis aims to
improve healthcare outcomes by enabling the practice of personalized
medicine anywhere, anytime. Biocartis' ambition is to establish a new
gold standard in diagnostic testing. Biocartis' innovative research
and diagnostic systems are characterized by multiplex detection and
simplified workflows which require less hands-on time and minimize
sample requirements (especially for tumor biopsies). Additionally,
Biocartis develops assays which have high clinical utility and
compelling health economic value. Oncology is the primary focus of
Biocartis as this is one of the greatest unmet needs for personalized
medicine. Biocartis is well suited to address the growing need for
individualized diagnosis and treatment of cancer patients.

Biocartis is a rapidly growing company; to date Biocartis staff
includes over 170 people.

ots Originaltext: Biocartis
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Contact Rudi Pauwels, CEO, Tel: +32-15-632-600 (Mechelen) , Tel:
+41-21-694-04-30 (Lausanne) , nhutsebaut@biocartis.com